Get the Stockscreener App
125.01
1.58%
1.94
After Hours:
125.00
-0.01
-0.01%
Sarepta Therapeutics Inc stock is traded at $125.01, with a volume of 822.83K.
It is up +1.58% in the last 24 hours and up +3.83% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
See More
Previous Close:
$123.07
Open:
$123
24h Volume:
822.83K
Relative Volume:
0.94
Market Cap:
$11.92B
Revenue:
$1.50B
Net Income/Loss:
$47.30M
P/E Ratio:
-15.97
EPS:
-7.83
Net Cash Flow:
$-527.92M
1W Performance:
-3.99%
1M Performance:
+3.83%
6M Performance:
-6.47%
1Y Performance:
+60.25%
1-Day Range:
$121.18
$125.25
1-Week Range:
$121.01
$130.85
52-Week Range:
$75.85
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Allspring Global Investments Holdings LLC Sells 21,269 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Emerald Advisers LLC Has $1.04 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Gladstone Institutional Advisory LLC Acquires 26,900 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Interesting SRPT Put And Call Options For December 13th - Nasdaq
Pinnacle Associates Ltd. Has $11.48 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (SRPT) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by abrdn plc - MarketBeat
China Universal Asset Management Co. Ltd. Has $2.29 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Sarepta’s Recent Elevidys Presentations Leave Duchenne Community Wanting - BioSpace
Sarepta Therapeutics, Inc. (SRPT): An Unstoppable Stock That Could Make You Richer - Insider Monkey
8 Unstoppable Stocks That Could Make You Richer - Insider Monkey
Assenagon Asset Management S.A. Has $43.72 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics' SWOT analysis: stock poised for growth as Elevidys expands DMD market reach - Investing.com
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results - BioSpace
Q2 EPS Estimate for Sarepta Therapeutics Lifted by Analyst - MarketBeat
Zacks Research Issues Positive Forecast for SRPT Earnings - MarketBeat
Exploring High Growth Tech Stocks In United States October 2024 - Simply Wall St
Sarepta a new buy at Jefferies on muscular dystrophy franchise, pipeline - MSN
Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights - Benzinga
Royal Bank of Canada Reaffirms Outperform Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Sarepta stock a 'buy' as Jefferies forecasts $4B peak sales from DMD gene therapy - Investing.com Canada
Sarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from Analysts at Jefferies Financial Group - MarketBeat
Unveiling 15 Analyst Insights On Sarepta Therapeutics - Benzinga
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment? - Simply Wall St
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $183.89 Consensus Price Target from Analysts - MarketBeat
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds? - Insider Monkey
Sarepta upgraded at Oppenheimer on potential Elevidys label expansion - MSN
Muscular Dystrophy Treatment Market Transformative Trends: - openPR
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way - GlobeNewswire Inc.
Sarepta Therapeutics (NASDAQ:SRPT) Rating Reiterated by Needham & Company LLC - MarketBeat
Barclays maintains Overweight rating on Sarepta Therapeutics shares By Investing.com - Investing.com UK
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5%Should You Buy? - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Given "Outperform" Rating at Raymond James - MarketBeat
Gene Therapy For Rare Disease Market Report: Growth Forecast - openPR
Limb Girdle Muscular Dystrophy Market 2024-2031Jubilant Cadista Pharmaceuticals Inc., Sarepta Therapeutics, Inc. - openPR
Sarepta shares hold as BMO maintains Outperform rating on Elevidy data - Investing.com UK
Connective Portfolio Management LLC Takes $1.62 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial - Nature.com
Sei Investments Co. Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics - Benzinga
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $182.00 at Royal Bank of Canada - MarketBeat
Clearbridge Investments LLC Boosts Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Six biotechs driving progress in Duchenne muscular dystrophy - Labiotech.eu
Teachers Retirement System of The State of Kentucky Purchases New Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):